Overview

This trial is active, not recruiting.

Condition arthroplasty, replacement, hip
Treatments trident cup, x3 inserts, 28 mm head, trident cup, x3 inserts, 40 mm head, symax stem, accolade tmzf stem
Sponsor Stryker European Operations BV
Start date October 2010
End date March 2018
Trial size 40 participants
Trial identifier NCT02525627, H-S-045

Summary

Prospective, singlecentre, randomized clinical study; series of patients with a 5-years patient evaluation period.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
trident cup, x3 inserts, 28 mm head
Orthopaedic implant
symax stem
Orthopaedic implant
accolade tmzf stem
Orthopaedic implant
(Active Comparator)
Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
trident cup, x3 inserts, 40 mm head
Orthopaedic implant
symax stem
Orthopaedic implant
accolade tmzf stem
Orthopaedic implant

Primary Outcomes

Measure
Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes using HAS (Hip Analysis Suite, a software for the determination of polyethylene wear on digital radiographs).
time frame: 5 years follow-up

Secondary Outcomes

Measure
Harris Hip Score (HHS) patient questionnaire
time frame: pre-operative, at day of discharge (up to 5 days post-operative), 3 months, 1,2 and 5 years
Merle D'Aubergine Score (MdA)
time frame: pre-operative, at day of discharge (up to 5 days post-operative), 3 months, 1,2 and 5 years

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. Male and non pregnant female patients between 18-75 years of age. 2. Patients requiring uncemented primary total hip arthroplasty (THA), suitable for the use of the Symax stem 3. Patients with a diagnosis of osteoarthritis (OA), rheumatoid arthritis (RA), avascular necrosis (AVN) or post-traumatic arthritis (TA). 4. Patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical and radiographic evaluations and the prescribed rehabilitation 5. Patients who signed the specific Informed Consent Form prior to surgery Exclusion Criteria: 1. Patients who require revision of a previously implanted THA 2. Patients who had a THA on contra-lateral side within the last 1 year. 3. Patients who had a THA on contralateral side more than 1 year ago and the rehabilitation period outcome was considered unsatisfactory or not good. (Patients with contra-lateral THA > 1 year ago with good outcome (Harris Hip Score > 85) can be included in the study). 4. Patients who will need lower limb joint replacement for another joint within one year. 5. Bilaterally operated patient. 6. Patients who have had a prior procedure of acetabular osteotomy. 7. Patients with active or suspected infection. 8. Patients with malignancy - active malignancy 9. Patients with a diagnosed systemic disease that would affect the subject's welfare or overall outcome of the study (i.e. severe osteoporosis, Paget's disease, renal osteodystrophy) or is immunologically suppressed, or receiving steroids in excess of physiologic dose requirements. 10. The patient has a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period. 11. Female patients planning a pregnancy during the course of the study. 12. Patients with systemic or metabolic disorders leading to progressive bone deterioration. 13. Patients, who as judged by the surgeon, are mentally incompetent or are unlikely to be compliant with the prescribed post-operative routine and follow-up evaluation schedule. 14. Patients with other severe concurrent joint involvements which can affect their outcome. 15. Patients with other concurrent illnesses which are likely to affect their outcome such as sickle cell anaemia, systemic lupus erythematosus, psoriasis, Insulin dependent Type I diabetes or renal disease requiring dialysis. 16. Surgeries to be performed with navigation and/or robot-assisted instruments. 17. Patient with a known sensitivity to device materials.

Additional Information

Official title A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads With Highly Cross Linked (X3) Acetabular Polyethylene Insert in the Hemispherical Trident Cup
Principal investigator Ide C. Heyligers, MD
Description This is a single centre randomized clinical outcomes study. The Symax stem or Accolade TMZF (Titan, Molybdenum, Zirconium, Ferrum) in combination with the Hemispherical Trident cup, X3 inserts, 28 and 40 mm Metal heads are the primary components to be implanted for evaluation.
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by Stryker European Operations BV.